Immediate Impact
50 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
2024 Standout
Works of Gavin Taylor‐Stokes being referenced
The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study
2013
Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany
2013
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Gavin Taylor‐Stokes | 419 | 449 | 67 | 190 | 47 | 959 | |
| Roger J. Black | 216 | 326 | 19 | 82 | 31 | 1.1k | |
| Joris Diels | 215 | 209 | 34 | 203 | 109 | 1.0k | |
| Derek Tang | 218 | 202 | 13 | 205 | 74 | 906 | |
| Joseph F. O’Donnell | 131 | 194 | 20 | 236 | 29 | 949 | |
| Anna Ceribelli | 441 | 567 | 35 | 37 | 35 | 1.0k | |
| Paul Rebattu | 431 | 566 | 26 | 82 | 55 | 913 | |
| Gerald E. Metter | 156 | 392 | 15 | 97 | 21 | 764 | |
| Sabrina Trippoli | 119 | 200 | 21 | 138 | 90 | 835 | |
| Francesco Cottone | 117 | 309 | 11 | 287 | 59 | 1.1k | |
| Isabella C. Glitza | 302 | 561 | 20 | 33 | 44 | 911 |
All Works
Login with ORCID to disown or claim papers
Loading papers...